Paper Details

  1. Home
  2. Paper Details

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

Author: BowmanD M, BryantJ, CostantinoJ, DeCillisA, DeschênesL, DignamJ, DimitrovN V, EvansJ, FarrarW, FeldmanM I, FisherB, FisherE R, LickleyH L, MargoleseR G, PatersonA H, RedmondC, RobidouxA, ShibataH, TerzJ, WickerhamD L, WolmarkN

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Tamoxifen therapy provided substantial benefit to patients with early stage breast cancer.
Paper Details　
Original Abstract of the Article :
In 1982, the National Surgical Adjuvant Breast and Bowel Project initiated a randomized, double-blinded, placebo-controlled trial (B-14) to determine the effectiveness of adjuvant tamoxifen therapy in patients with primary operable breast cancer who had estrogen receptor-positive tumors and no axill...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jnci/88.21.1529

データ提供：米国国立医学図書館（NLM）

Tamoxifen: A Powerful Tool in the Battle Against Breast Cancer

The fight against breast cancer is a relentless journey, often requiring a multi-faceted approach. Tamoxifen, a powerful anti-estrogen drug, has proven to be a valuable weapon in this battle. A pivotal study, known as B-14, demonstrated the significant benefits of adjuvant tamoxifen therapy in patients with early-stage, estrogen receptor-positive breast cancer and negative axillary lymph nodes. These findings were like a beacon of hope in the vast desert of breast cancer research, offering a new path to survival and improved outcomes for patients.

The Quest for Optimal Duration of Tamoxifen Therapy

While the initial findings of B-14 were encouraging, questions arose regarding the optimal duration of tamoxifen therapy. Researchers sought to determine how long the observed benefits would persist and how long treatment should continue to maximize these benefits. The researchers sought to map the optimal duration of therapy, much like a cartographer charting a vast desert landscape. This research is crucial to ensure patients receive the most effective treatment while minimizing potential side effects.

Tamoxifen: Balancing Benefits and Risks

Like any powerful tool, tamoxifen carries its own set of potential risks, including adverse effects from prolonged treatment. This study highlights the importance of carefully weighing the benefits and risks of tamoxifen therapy to determine the optimal treatment plan for each patient. Navigating this delicate balance requires careful consideration and a collaborative approach between the patient and their healthcare team, ensuring that the benefits of treatment outweigh the potential risks.

Dr. Camel's Conclusion

The study of tamoxifen therapy has illuminated a crucial path in the fight against breast cancer, providing a valuable tool for improving patient outcomes. However, just like a camel trekking across a vast desert, it's essential to carefully consider the nuances of this treatment, weighing the potential benefits against the risks to ensure the best possible outcome for each individual patient.

Date :
  1. Date Completed 1996-12-04
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

8901851

DOI: Digital Object Identifier

10.1093/jnci/88.21.1529

Related Literature

Article Analysis
・Effects of tamoxifen
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.